In this @-week , double-blind , placebo-controlled ( up to Week @ ) study ( NCT@ ) , patients responding inadequately to disease-modifying antirheumatic drugs ( DMARD ) or biologics were randomized to receive monthly subcutaneous injections of secukinumab ( @ , @ , @ , or @ mg ) , or placebo .